Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Xspray Pharma AB ( (SE:XSPRAY) ).
Xspray Pharma reported its Q1 2025 financial results, highlighting a net sales figure of SEK 0 thousand and a loss before tax of SEK -42,321 thousand. Significant developments included the re-submission of the market approval application for Dasynoc® to the FDA and positive interim data from a study on XS003 nilotinib, demonstrating stable bioavailability. These advancements underscore the potential impact of Xspray’s technology on patient care and its strategic positioning in the oncology drug market.
More about Xspray Pharma AB
Xspray Pharma AB operates in the pharmaceutical industry, focusing on developing improved versions of existing drugs using its proprietary HyNap™ technology platform. The company primarily targets the oncology market with its lead product candidates, including Dasynoc® and XS003 nilotinib.
Average Trading Volume: 19,600
Current Market Cap: SEK1.05B
Find detailed analytics on XSPRAY stock on TipRanks’ Stock Analysis page.